Brooks R J, Jones S E, Salmon S E, Chase E M, Davis S L, Moon T E, Giordano G F, Ketchel S J, Jackson R A
NCI Monogr. 1986(1):135-7.
One hundred fifty-six women with axillary node-negative breast cancer and primary tumors less than or equal to 5 cm in diameter (T1N0 or T2N0) were treated with a brief course of postoperative adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide. Treatment was well tolerated and toxicity was minimal. With a median follow-up time of 58 months, there has been 1 relapse among 58 patients with T1 primary lesions and 15 relapses among 98 patients with T2 primary tumors. When compared with a matched historical control group receiving surgery alone, significant improvement was apparent in disease-free survival among the patients who received adjuvant chemotherapy. Prospective controlled trials are needed if we are to confirm this favorable experience with adjuvant chemotherapy in the treatment of women with node-negative breast cancer.
156例腋窝淋巴结阴性、原发肿瘤直径小于或等于5 cm（T1N0或T2N0）的乳腺癌女性患者接受了由阿霉素和环磷酰胺组成的短期术后辅助化疗。治疗耐受性良好，毒性极小。中位随访时间为58个月，58例T1原发灶患者中有1例复发，98例T2原发肿瘤患者中有15例复发。与仅接受手术的匹配历史对照组相比，接受辅助化疗的患者无病生存率有显著改善。如果我们要证实辅助化疗在治疗淋巴结阴性乳腺癌女性患者中的这种良好经验，还需要进行前瞻性对照试验。
